Novartis receives FDA approval 177Lu-PSMA-617 for metastatic castration resistant prostate cancer


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
FDA breakthrough therapy for Novartis metastatic prostate cancer drug

Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to 177 Lu-PSMA-617, an investigational radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Breakthrough Therapy designation is granted to medicines being evaluated for serious conditions where early clinical evidence indicates the potential for substantial improvement over available therapy1.

Breakthrough therapy designation granted based on positive data from the pivotal, Phase III VISION study evaluating 177 Lu-PSMA-617, a targeted radioligand therapy, plus standard of care (SOC), compared to SOC alone, in patients with progressive PSMA-positive mCRPC2.


Phase III VISION study demonstrated that 177 Lu-PSMA-617 significantly improved overall survival and radiographic progression-free survival for men with progressive PSMA-positive mCRPC2
The five-year survival rate for patients with metastatic prostate cancer is approximate 30%.

Novartis is a global leader in radioligand therapy, uniquely positioned with broad commercial experience, established manufacturing and supply chain capabilities, and extensive development expertise

Two additional studies with 177 Lu-PSMA-617 radioligand therapy in earlier lines of treatment for metastatic prostate cancer are ongoing, investigating potential clinical utility in the mCRPC pre-taxane setting (PSMAfore) and in the metastatic hormone-sensitive setting (PSMAddition).

Tags : #Prostate #metastaticProstateCancer #FDAApproval #FDANewsLatest #Novartis

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026